Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IlluminaXSWX:ILMN 76 Days Sales Outstanding is 58.69 as of Jun. 2026, which is 4% above its 10-year median of 56.46. GuruFocus rates XSWX:ILMN with a GF Score™ of 76/100 and a GF Value™ of CHF107.32. The stock has 7 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Illumina ranks better than 56.44% on this metric.
Illumina's average Accounts Receivable for the
three
months ended in Jun. 2026 was CHF596 Mil. Illumina's Revenue for the
three
months ended in Jun. 2026 was CHF926 Mil.
Hence, Illumina's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 58.69.
The historical rank and industry rank for Illumina's Days Sales Outstanding or its related term are showing as below:
XSWX:ILMN'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.77 Med: 56.46 Max: 66.77
Current: 61.51
During the past 13 years, Illumina's highest Days Sales Outstanding was 66.77. The lowest was 45.77. And the median was 56.46.
XSWX:ILMN's Days Sales Outstanding is ranked better than 56.44% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.855
vs XSWX:ILMN: 61.51
Illumina's Days Sales Outstanding
declined
from Jun. 2025 (62.92) to Jun. 2026 (58.69).
Illumina (XSWX:ILMN) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Illumina Days Sales Outstanding Related Terms
Illumina Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Illumina's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ILMN vs MTD, DGX, LH: Days Sales Outstanding Comparison
For the Diagnostics & Research subindustry, Illumina's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Illumina Days Sales Outstanding vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Illumina's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Illumina (XSWX:ILMN) has a Days Sales Outstanding of 58.69 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Illumina and its competitors. This is near median its historical median of 56.46. Over the past decade, Illumina's Days Sales Outstanding has ranged from 45.77 to 66.77. According to the industry distribution chart, Illumina ranks #88 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 43.6%.
Is Illumina's Days Sales Outstanding too high?
Illumina's current Days Sales Outstanding of 58.69 is near median its 10-year median of 56.46. Over the past 10 years, this metric has ranged from a low of 45.77 to a high of 66.77. The Medical Diagnostics & Research industry median Days Sales Outstanding is 67.86. Illumina's value of 58.69 is 13.5% below this industry median. Based on the distribution chart, Illumina ranks #88 out of 202 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Illumina has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Illumina's Days Sales Outstanding compare to MTD and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Illumina ranks #88 out of 202 companies for Days Sales Outstanding. This puts Illumina in the upper half of its industry. The industry median Days Sales Outstanding is 67.86. Illumina's value of 58.69 is 13.5% below this benchmark. Historically, Illumina's own Days Sales Outstanding has ranged from 45.77 to 66.77 over the past decade. While the company's 10-year median is 56.46 vs. the industry median of 67.86, Illumina has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Diagnostics & Research company?
The median Days Sales Outstanding among Medical Diagnostics & Research companies is 67.86, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Illumina's current Days Sales Outstanding of 58.69 is 13.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Illumina and its competitors. For the Medical Diagnostics & Research industry, the median Days Sales Outstanding is 67.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Illumina's current Days Sales Outstanding is 58.69, which is near median its own 10-year median of 56.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Illumina stock overvalued right now?
Illumina (XSWX:ILMN) has a current Days Sales Outstanding of 58.69. The stock's GF Value™ is CHF107.32, compared to a current price of CHF155.14 — trading 44.6% above its estimated fair value. The current Days Sales Outstanding is 58.69, which is near median its 10-year median of 56.46 and 13.5% below the Medical Diagnostics & Research industry median of 67.86. Illumina's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Illumina (XSWX:ILMN), the current Days Sales Outstanding is 58.69 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Illumina (XSWX:ILMN) Overvalued in 2026?
Based on GuruFocus' analysis, Illumina stock appears to be overvalued.
The current stock price of CHF155.14 is trading 44.6% above its estimated GF Value™ of CHF107.32.
Key valuation signals for XSWX:ILMN:
Days Sales Outstanding: 58.69 (near median its 10-year median of 56.46)
GF Value™: CHF107.32 vs. price of CHF155.14 (44.6% above fair value)
Industry Position: 13.5% below the Medical Diagnostics & Research median (#88 of 202)
No single metric tells the full story. See the XSWX:ILMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
76GF Score
Get the complete analysis for XSWX:ILMN
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ILMN has been successfully added to your 
